Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.47 |
| ▸ | CA2 | P00918 | 12/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078772 | 0.90 | CA2 (0.51) | CA1CA2CA4CA7CA5A | |
| SCHEMBL10059589 | 0.85 | CA2 (0.65) | CA1CA2CA4CA7CA5A | |
| SCHEMBL10059532 | 0.80 | CCNC (0.49) | CA1CA2CA5ACA5BCA12 | |
| SCHEMBL10059496 | 0.80 | CA1 (0.61) | CA1CA2CA4CA7CA5A | |
| SCHEMBL16474708 | 0.80 | CA1 (0.61) | CA1CA2CA4CA7CA5A | |
| SCHEMBL16474710 | 0.80 | PTGS2 (0.56) | CA1CA2CA4CA7CA5A | |
| SCHEMBL10079417 | 0.80 | CA2 (0.58) | CA1CA2CA4CA7CA5A | |
| SCHEMBL16474731 | 0.80 | HTR1B (0.43) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL10059534 | 0.79 | DRD2 (0.41) | — | |
| SCHEMBL10059518 | 0.79 | KDM4E (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2296653-B1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010135470-A1 | PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | CA1 4552/4885CA2 3612/4885CA4 3144/4885 |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | CA1 4695/4885CA2 4364/4885CA4 4618/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | CA1 4695/4885CA2 4364/4885CA4 4618/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | CA1 4642/4885CA2 4060/4885CA4 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.